NEUP
Neuphoria Therapeutics Inc.Company Information
- Company Name
- Neuphoria Therapeutics Inc.
- CIK
- CIK0001191070
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- NEUP: Nasdaq
- Fiscal Year End
- June 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NEUP
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-10-21
- Last sale
- —
- Shares purchased (TTM)
- 639,110
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,944,677
- Shares outstanding
- 4,395,776
- Ownership
- 44.24%
Earnings Market Reaction
- Filing date
- 2026-09-18
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 20 | 19 | 22 | 14 | 14 | 17 | 4 | 8 | 13 | ||||||
| Accounts Receivable Net Current | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Current | - | - | 0 | 0 | 0 | - | - | - | - | ||||||
| Prepaid Expense Current | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 21 | 22 | 23 | 14 | 15 | 17 | 4 | 8 | 13 | ||||||
| Property Plant And Equipment Net | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Goodwill | 3 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 9 | ||||||
| Assets | 29 | 35 | 37 | 27 | 29 | 31 | 18 | 23 | 28 | ||||||
Liabilities Current | |||||||||||||||
| Accounts Payable Current | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | ||||||
| Accrued Liabilities And Other Liabilities | 0 | 1 | 2 | 4 | 3 | 1 | 0 | 1 | 1 | ||||||
| Operating Lease Liability Current | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 1 | 2 | 3 | 5 | 4 | 2 | 2 | 3 | 4 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | ||||||
| Deferred Income Tax Liabilities Net | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Warrants And Rights Outstanding | 2 | 2 | 3 | 8 | 4 | 2 | 1 | 2 | 5 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 4 | 5 | 7 | 15 | 10 | 5 | 4 | 6 | 10 | ||||||
Stockholders Equity | |||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | ||||||
| Additional Paid In Capital | 218 | 218 | 218 | 204 | 200 | 199 | 198 | 198 | 198 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -2 | -2 | -3 | -3 | -4 | -4 | -2 | -3 | ||||||
| Retained Earnings Accumulated Deficit | -192 | -187 | -186 | -188 | -178 | -169 | -181 | -179 | -178 | ||||||
| Stockholders Equity | 25 | 29 | 30 | 13 | 19 | 26 | 14 | 17 | 17 | ||||||
| Liabilities And Stockholders Equity | 29 | 35 | 37 | 27 | 29 | 31 | 18 | 23 | 28 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | ||||||
| Common Stock Shares Issued | 5 | 5 | 5 | 2 | 2 | 2 | 2 | 3 | 1 | ||||||
| Shares Outstanding | 5 | 5 | 5 | 2 | 2 | 2 | 2 | 3 | 1 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNeuphoria Therapeutics Inc. (NEUP) — SEC Financial Statements & Analysis
Neuphoria Therapeutics Inc. (NEUP) is a pharmaceutical preparations company, incorporated in C3. Neuphoria Therapeutics Inc. trades on Nasdaq as: NEUP. Neuphoria Therapeutics Inc. (NEUP)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-18. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Neuphoria Therapeutics Inc. carries a market cap of $19.21M, a P/E ratio of -1.43x, a P/B ratio of 0.78x, a P/S ratio of -1660.04x, an enterprise value of $-655.99K, and an EV/EBITDA multiple of 0.04x. On profitability, it posts an operating margin of 126329.97%, a net margin of 131387.14%, a Return on Equity (ROE) of -61.70%, a Return on Assets (ROA) of -46.95%, and a Return on Invested Capital (ROIC) of -337.06%. Per share, it reports EPS of $-3.06, diluted EPS of $-3.06, free cash flow per share of $-2.81, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 3539.28% year-over-year, and EPS growth of 1243.62% year-over-year. On the balance sheet, it maintains a current ratio of 27.85x, a quick ratio of 27.33x, working capital of $20.31M, a debt-to-equity ratio of 0.17x, a debt ratio of 0.14, free cash flow of $-12.35M (TTM), and net debt of $-19.87M. Figures sourced from SEC EDGAR.
- Market Cap
- $19.21M
- P/E TTM
- -1.43x
- EPS TTM
- $-3.06
- P/B TTM
- 0.78x
- ROE TTM
- -61.70%
- ROA TTM
- -46.95%
- Debt To Equity
- 0.17x
- Free Cash Flow TTM
- $-12.35M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Neuphoria Therapeutics Inc. in?
Neuphoria Therapeutics Inc. (NEUP) operates in the Pharmaceutical Preparations industry.
What exchange does NEUP trade on?
Neuphoria Therapeutics Inc. (NEUP) trades on the Nasdaq.
Where is Neuphoria Therapeutics Inc. incorporated?
Neuphoria Therapeutics Inc. is incorporated in Australia.
When was Neuphoria Therapeutics Inc. (NEUP)'s most recent SEC filing?
Neuphoria Therapeutics Inc. (NEUP)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-18.
What is NEUP's market cap?
Neuphoria Therapeutics Inc. (NEUP) has a market capitalization of $19.21M as of 2026-06-30.
What is NEUP's EPS (earnings per share)?
Neuphoria Therapeutics Inc. (NEUP)'s trailing twelve month EPS is $-3.06 as of 2026-06-30.
What is NEUP's ROE (return on equity)?
Neuphoria Therapeutics Inc. (NEUP)'s trailing twelve month Return on Equity (ROE) is -61.70% as of 2026-06-30.
What is NEUP's ROA (return on assets)?
Neuphoria Therapeutics Inc. (NEUP)'s trailing twelve month Return on Assets (ROA) is -46.95% as of 2026-06-30.
What is NEUP's ROIC (return on invested capital)?
Neuphoria Therapeutics Inc. (NEUP)'s trailing twelve month Return on Invested Capital (ROIC) is -337.06% as of 2026-06-30.
What is NEUP's EV/EBITDA?
Neuphoria Therapeutics Inc. (NEUP)'s trailing twelve month EV/EBITDA is 0.04x as of 2026-06-30.